Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) EBT (2016 - 2025)

Cryo Cell International (CCEL) has disclosed EBT for 16 consecutive years, with -$4.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 449.83% to -$4.6 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$2.3 million, a 183.35% decrease, with the full-year FY2025 number at -$2.3 million, down 183.35% from a year prior.
  • EBT was -$4.6 million for Q4 2025 at Cryo Cell International, down from $1.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $1.6 million in Q2 2021 to a low of -$16.0 million in Q4 2023.
  • A 5-year average of -$348367.4 and a median of $847145.0 in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 2669.13% in 2023, then surged 324.98% in 2024.
  • Cryo Cell International's EBT stood at -$1.2 million in 2021, then soared by 150.05% to $622508.0 in 2022, then crashed by 2669.13% to -$16.0 million in 2023, then surged by 94.73% to -$842434.0 in 2024, then tumbled by 449.83% to -$4.6 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's EBT are -$4.6 million (Q4 2025), $1.2 million (Q3 2025), and $575103.0 (Q2 2025).